Patents Represented by Attorney, Agent or Law Firm Law Offices of Jane Massey Licata
  • Antisense modulation of MEKK5 expression
    Patent number: 6080546
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEKK5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEKK5. Methods of using these compounds for modulation of MEKK5 expression and for treatment of diseases associated with expression of MEKK5 are provided.
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: June 27, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, William Gaarde, Lex M. Cowsert
  • Antisense modulation of TRADD expression
    Patent number: 6077672
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of TRADD. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TRADD. Methods of using these compounds for modulation of TRADD expression and for treatment of diseases associated with expression of TRADD are provided.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: June 20, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Survivin expression
    Patent number: 6077709
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Survivin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Survivin. Methods of using these compounds for modulation of Survivin expression and for treatment of diseases associated with expression of Survivin are provided.
    Type: Grant
    Filed: September 29, 1998
    Date of Patent: June 20, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Eric E. Swayze, Lex M. Cowsert
  • Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
    Patent number: 6077833
    Abstract: Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.
    Type: Grant
    Filed: December 31, 1996
    Date of Patent: June 20, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Timothy A. Vickers
  • Antisense modulation of NF-kappa-B p65 subunit expression
    Patent number: 6069008
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of NF-kappa-B p65 subunit. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding NF-kappa-B p65 subunit. Methods of using these compounds for modulation of NF-kappa-B p65 subunit expression and for treatment of diseases associated with expression of NF-kappa-B p65 subunit are provided.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: May 30, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of Beta catenin expression
    Patent number: 6066500
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Beta catenin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Beta catenin. Methods of using these compounds for modulation of Beta catenin expression and for treatment of diseases associated with expression of Beta catenin are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: May 23, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense inhibition of G-alpha-i3 expression
    Patent number: 6063626
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i3. Methods of using these compounds for modulation of G-alpha-i3 expression and for treatment of diseases associated with expression of G-alpha-i3 are provided.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: May 16, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense inhibition of ETs-2 expression
    Patent number: 6054316
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Ets-2. The compositions comprise antisense com ounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ets-2. Methods of using these compounds for modulation of Ets-2 expression and for treatment of diseases associated with expression of Ets-2 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 25, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert
  • Antisense inhibition of Jun N-terminal Kinase Kinase-2 expression
    Patent number: 6054440
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Jun N-terminal Kinase Kinase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Jun N-terminal Kinase Kinase-2. Methods of using these compounds for modulation of Jun N-terminal Kinase Kinase-2 expression and for treatment of diseases associated with expression of Jun N-terminal Kinase Kinase-2 are provided.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: April 25, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Compositions and methods for targeting cells and modulating pulmonary surfactant secretion
    Patent number: 6051224
    Abstract: Methods of modulating pulmonary surfactant secretion and treating conditions such as respiratory distress syndrome, are provided. Compositions for delivering imaging and therapeutic agents through use of the monoclonal antibodies A2C and A2R or fragments thereof are provided. Methods for delivering selected effector molecules such as imaging, modulating and therapeutic agents through use of these compositions are also provided.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: April 18, 2000
    Assignee: Thomas Jefferson University
    Inventors: David S. Strayer, Avinash Chander
  • Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
    Patent number: 6051237
    Abstract: Vaccines containing recombinant Listeria monocytogenes capable of expressing tumor specific antigens are provided. These vaccines, when administered to a host, are capable of inducing an immune response to the tumor specific antigen. Methods of using these vaccines in the suppression tumor formation are also provided.
    Type: Grant
    Filed: November 8, 1994
    Date of Patent: April 18, 2000
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Yvonne Paterson
  • Sensor laminates and multi-sectioned fluid delivery devices for detecting by immunoassay target molecules in biological fluids
    Patent number: 6048735
    Abstract: Sensor laminates for detection by immunoassay of target molecules in biological fluids wherein the sensor laminates contain a reactive substrate layer having a polymeric material treated to enhance binding to a ligand and methods of producing and using these sensor laminates are provided. Also provided are multi-sectioned fluid delivery devices for use with the sensor laminates in detection of target molecules in biological fluids.
    Type: Grant
    Filed: December 4, 1997
    Date of Patent: April 11, 2000
    Assignee: Idego ApS
    Inventors: Lasse Leif Hessel, Jorgen Schjerning Lundsgaard, Jesper Malling
  • Antisense modulation of MDMX expression
    Patent number: 6046320
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MDMX. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MDMX. Methods of using these compounds for modulation of MDMX expression and for treatment of diseases associated with expression of MDMX are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: April 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of PI3 kinase p110 delta expression
    Patent number: 6046049
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3 kinase p110 delta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3 kinase p110 delta. Methods of using these compounds for modulation of PI3 kinase p110 delta expression and for treatment of diseases associated with expression of PI3 kinase p110 delta are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: April 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of G-alpha-i1 expression
    Patent number: 6046321
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i1. Methods of using these compounds for modulation of G-alpha-i1 expression and for treatment of diseases associated with expression of G-alpha-i1 are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: April 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense modulation of liver glycogen phosphorylase expression
    Patent number: 6043091
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of liver glycogen phosphorylase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding liver glycogen phosphorylase. Methods of using these compounds for modulation of liver glycogen phosphorylase expression and for treatment of diseases associated with expression of liver glycogen phosphorylase are provided.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: March 28, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of human Akt-2 expression
    Patent number: 6043090
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Akt-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Akt-2. Methods of using these compounds for modulation of Akt-2 expression and for treatment of diseases associated with expression of Akt-2 are provided.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: March 28, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of Smad5 expression
    Patent number: 6040178
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Smad5. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Smad5. Methods of using these compounds for modulation of Smad5 expression and for treatment of diseases associated with expression of Smad5 are provided.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: March 21, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of G-alpha-i2 expression
    Patent number: 6040179
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-i2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-i2. Methods of using these compounds for modulation of G-alpha-i2 expression and for treatment of diseases associated with expression of G-alpha-i2 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 21, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense inhibition of integrin beta 3 expression
    Patent number: 6037176
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of integrin beta 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding integrin beta 3. Methods of using these compounds for modulation of integrin beta 3 expression and for treatment of diseases associated with expression of integrin beta 3 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: March 14, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Brett P. Monia, Lex M. Cowsert